News

Pfizer in Advanced Talks to Buy Global Blood Therapeutics for About $5 Billion

Pfizer is aiming to seal a deal for GBT in the coming days.Photo: Andrew Seng for The Wall Street Journal

Pfizer is in advanced talks to buy Global Blood Therapeutics the maker of a recently approved drug for sickle-cell disease, for about $5 billion, in the latest move by the drug giant to bolster its portfolio and pipeline.

Pfizer is aiming to seal a deal for GBT in the coming days, according to people familiar with the matter. The situation is still fluid, and other suitors are still in the mix, some of the people said. GBT announces its second-quarter results Monday.

Sponsored Offers

Most Popular news

Most Popular opinion

Recommended Videos

What is your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in:News